Special Issue

Head and Neck Cancer: From Mechanisms to Therapeutic Approaches—Advances and Challenges

Message from the Guest Editors

Head and neck cancers (HNCs) represent a complex and diverse group of malignancies with significant global health impact. Despite advancements in understanding their pathogenesis and management, outcomes for many patients remain poor, particularly in advanced stages. This Special Issue aims to highlight recent progress in the field and promote multidisciplinary research linking basic, translational, and clinical sciences. Key areas of interest include molecular and cellular mechanisms driving tumor development and progression, the role of human papillomavirus in oncogenesis, and new perspectives on the tumor microenvironment. Contributions exploring innovative therapeutic strategies, including immunotherapies, targeted therapies and multimodal approaches, as well as the discovery of biomarkers to improve diagnosis, prognosis and therapeutic monitoring are encouraged. This Special Issue will also consider studies on the psychosocial and functional impact of HNCs treatments, strategies to improve quality of life and progress in personalized medicine.

Guest Editors

Dr. Barbara Verro

Dr. Carmelo Saraniti

Dr. Daniela Carlisi

Deadline for manuscript submissions

31 August 2025



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/229190

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).